Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer
Published version of a preprint
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
miR-223 is an anti-inflammatory miRNA that in cancer acts either as an oncosuppressor or oncopromoter, in a context-dependent manner. In breast cancer, we demonstrated that it dampens the activation of the EGF pathway. However, little is known on the role of miR-223 during breast cancer onset and progression. miR-223 expression was decreased in breast cancer of luminal and HER2 subtypes and inversely correlated with patients' prognosis. In normal luminal mammary epithelial cells, miR-223 acted cell autonomously in the control of their growth and morphology in three-dimensional context. In the MMTV-Δ16HER2 transgenic mouse model, oncogene transformation resulted in a timely abrogation of miR-223 expression, likely due to activation of E2F1, a known repressor of miR-223 transcription. Accordingly, treatment with CDK4/6 inhibitors, which eventually results in restraining E2F1 activity, restored miR-223 expression and miR-223 ablation induced luminal breast cancer resistance to CDK4/6 inhibition, both in vitro and in vivo. Notably, miR-223 expression was lost in microdissected ductal carcinoma in situ (DCIS) from patients with luminal and HER2-positive breast cancer. Altogether, these results identify downmodulation of miR-223 as an early step in luminal breast cancer onset and suggest that it could be used to identify aggressive DCIS and predict the response to targeted therapy. Significance: miR-223 may represent a predictive biomarker of response to CDK4/6 inhibitors and its loss could identify DCIS lesions that are likely to progress into invasive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, it could control the growth and morphology of mammary epithelial cells 64.”
From miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation (2021) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of progenitor cell proliferation and granulocyte function by microRNA-223
Johnnidis, J. B., Harris, M. H., Wheeler, R. T., Stehling-Sun, S., Lam, M. H., Kirak, O., Brummelkamp, T. R., Fleming, M. D., & Camargo, F. D. (2008) · Nature · doi:10.1038/nature06607 · Cited by 1,208
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., Alvarado, M., Flyger, H. L., Massarut, S., Eiermann, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60837-9 · Cited by 772
Self-citation
Research works printed but not linked: 35
- Dragomir, 2018, Using microRNA networks to understand cancer, Int J Mol Sci, 19, 10.3390/ijms19071871 · DOI
- Shah, 2016, microRNA therapeutics in cancer - an emerging concept, EBioMedicine, 12, 34, 10.1016/j.ebiom.2016.09.017 · DOI · Paper page
- Fabris, 2016, Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway, Oncogene, 35, 4914, 10.1038/onc.2016.23 · DOI
- Vaidya, 2014, Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 383, 603, 10.1016/S0140-6736(13)61950-9 · DOI · Paper page
- O'Connell, 2011, MicroRNA function in myeloid biology, Blood, 118, 2960, 10.1182/blood-2011-03-291971 · DOI · Paper page
- Jeffries, 2019, miRNA-223 at the crossroads of inflammation and cancer, Cancer Lett, 451, 136, 10.1016/j.canlet.2019.02.051 · DOI
- Masciarelli, 2014, Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells, Oncogene, 33, 1601, 10.1038/onc.2013.106 · DOI · Paper page
- Dong, 2017, MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation, Biochem Biophys Res Commun, 483, 630, 10.1016/j.bbrc.2016.12.091 · DOI
- Pinatel, 2014, miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions, PloS One, 9, e84859, 10.1371/journal.pone.0084859 · DOI
- Pulikkan, 2010, Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia, Blood, 115, 1768, 10.1182/blood-2009-08-240101 · DOI · Paper page
- Stamatopoulos, 2009, microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification, Blood, 113, 5237, 10.1182/blood-2008-11-189407 · DOI · Paper page
- Fassan, 2017, Early miR-223 upregulation in gastroesophageal carcinogenesis, Am J Clin Pathol, 147, 301, 10.1093/ajcp/aqx004 · DOI
- Streppel, 2013, microRNA 223 is upregulated in the multistep progression of barrett9s esophagus and modulates sensitivity to chemotherapy by targeting PARP1, Clin Cancer Res, 19, 4067, 10.1158/1078-0432.CCR-13-0601 · DOI · Paper page
- Armenia, 2014, Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner, Oncotarget, 5, 1185, 10.18632/oncotarget.1803 · DOI
- Barrio, 2017, Controversies in the treatment of DCIS, Annu Rev Med, 68, 197, 10.1146/annurev-med-050715-104920 · DOI
- Marchini, 2011, The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse, PloS One, 6, e18727, 10.1371/journal.pone.0018727 · DOI · Paper page
- Ince, 2007, Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes, Cancer Cell, 12, 160, 10.1016/j.ccr.2007.06.013 · DOI · Paper page
- Segatto, 2019, Stathmin is required for normal mouse mammary gland development and delta16HER2-driven tumorigenesis, Cancer Res, 79, 397, 10.1158/0008-5472.CAN-18-2488 · DOI
- Bakin, 2000, Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration, J Biol Chem, 275, 36803, 10.1074/jbc.M005912200 · DOI · Paper page
- Fabris, 2015, p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability, Proc Natl Acad Sci, 112, 13916, 10.1073/pnas.1508514112 · DOI
- Sonego, 2013, Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer, EMBO Mol Med, 5, 707, 10.1002/emmm.201201504 · DOI · Paper page
- Segatto, 2013, Inhibition of breast cancer local relapse by targeting p70S6 kinase activity, J Mol Cell Biol, 5, 428, 10.1093/jmcb/mjt027 · doi:10.1093/jmcb/mjt027
- Segatto, 2014, p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation, Mol Oncol, 8, 766, 10.1016/j.molonc.2014.02.006 · DOI
- Dall'Acqua, 2017, CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation, EMBO Mol Med, 9, 1415, 10.15252/emmm.201607012 · DOI
- Berton, 2014, Genetic characterization of p27kip1 and stathmin in controlling cell proliferation in vivo, Cell Cycle, 13, 3100, 10.4161/15384101.2014.949512 · DOI
- Citron, 2017, An integrated approach identifies mediators of local recurrence in head and neck squamous carcinoma, Clin Cancer Res, 23, 3769, 10.1158/1078-0432.CCR-16-2814 · DOI
- Nagy, 2018, Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets, Sci Rep, 8, 9227, 10.1038/s41598-018-27521-y · DOI · Paper page
- Kwong, 1998, A novel splice variant of HER2 with increased transformation activity, Mol Carcinog, 23, 62, 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O · DOI · Paper page
- Serra, 2013, Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation, Cancer Discov, 3, 1238, 10.1158/2159-8290.CD-13-0132 · DOI
- Yang, 2018, MicroRNA-223 targeting STIM1 inhibits the biological behavior of breast cancer, Cell Physiol Biochem, 45, 856, 10.1159/000487180 · doi:10.1159/000487180
- Sun, 2016, MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1, PloS One, 11, e0162754, 10.1371/journal.pone.0162754 · DOI
- Kang, 2012, Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer, PloS One, 7, e33919, 10.1371/journal.pone.0033919 · DOI
- Imura, 2017, miR-223 and stathmin-1 expression in non-tumor liver tissue of patients with hepatocellular carcinoma, Anticancer Res, 37, 5877
- Wong, 2008, MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1, Gastroenterology, 135, 257, 10.1053/j.gastro.2008.04.003 · DOI · Paper page
- Gianni, 2018, Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study, Lancet Oncol, 19, 249, 10.1016/S1470-2045(18)30001-9 · DOI · Paper page
Cited by
miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation
Jiao, P., Wang, X.-P., Luoreng, Z.-M., Yang, J., Jia, L., Ma, Y., & Wei, D.-W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59876 · Cited by 151
“For instance, it could control the growth and morphology of mammary epithelial cells [64].”
Background
Metadata
- Authors
- Citron, F., Segatto, I., Vinciguerra, G. L. R., Musco, L., Russo, F., Mungo, G., D'Andrea, S., Mattevi, M. C., Perin, T., Schiappacassi, M., Massarut, S., Marchini, C., Amici, A., Vecchione, A., Baldassarre, G., & Belletti, B.
- Affiliations
- 1Molecular Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- 3Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- 4Breast Surgery Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- 5Department of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.
- 2Faculty of Medicine and Psychology, Department of Clinical and Molecular Medicine, University of Rome “Sapienza” Sant'Andrea Hospital, Rome, Italy.
- ORCID
- Venue
- Cancer Research
- Published
- 2020-03-01
- Volume
- 80
- Issue
- 5
- Pages
- 1064-1077
- ISSN
- 0008-5472
- 1538-7445
- Cited by
- 55
- References
- 3
- Language
- en
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG 20061, #18171, #20902)
- CRO (5 × 1000_2016_MdS)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-1793
- The paper
- Citron, F., Segatto, I., Vinciguerra, G. L. R., Musco, L., Russo, F., Mungo, G., D'Andrea, S., Mattevi, M. C., Perin, T., Schiappacassi, M., Massarut, S., Marchini, C., Amici, A., Vecchione, A., Baldassarre, G., & Belletti, B. (2020). Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-1793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.